A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-controlled Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe Active Rheumatoid Arthritis
Latest Information Update: 12 May 2023
At a glance
- Drugs Zunsemetinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Aclaris Therapeutics
- 08 May 2023 According to an Aclaris Therapeutics media release, topline data is expected in the fourth quarter of 2023.
- 09 Nov 2021 Results assessing whether MK2 inhibition was well tolerated and could deliver sustained anti-inflammatory effect leading to durable clinical activity in patients with rheumatoid arthritis, presented at the ACR Convergence 2021.
- 24 Mar 2021 Status changed from active, no longer recruiting to completed.